<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a double-blind, placebo-controlled trial in thirty patients with mild to moderate vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VD) according to <z:chebi fb="4" ids="38624">DSM</z:chebi>-III-R criteria, the effects of the <z:chebi fb="3" ids="16335">adenosine</z:chebi> uptake blocker propentofylline (HWA 285) on regional cerebral <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism (rCMRGl) was studied using <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography of 2-[<z:chebi fb="0" ids="36939">18F</z:chebi>]fluoro-2-deoxy-<z:chebi fb="0" ids="4167">D-glucose</z:chebi> (FDG) </plain></SENT>
<SENT sid="1" pm="."><plain>25 subjects completed the 3-months study </plain></SENT>
<SENT sid="2" pm="."><plain>Propentofylline significantly improved relative rCMRGl in the motor cortex, while relative rCMRGl in the placebo treated group worsened significantly </plain></SENT>
<SENT sid="3" pm="."><plain>Neuropsychologically, visual information processing was improved in the propentofylline group and we observed a trend towards a slowing of the progression of <z:e sem="disease" ids="C0854193" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive deterioration</z:e> in patients with VD </plain></SENT>
<SENT sid="4" pm="."><plain>The results of the longitudinal analysis showed further that neuropsychological and metabolic changes are closely related </plain></SENT>
<SENT sid="5" pm="."><plain>These findings justify a large-scale clinical trial to prove therapeutic efficacy </plain></SENT>
</text></document>